Prime Medicine (PRME) Current Deferred Revenue (2024 - 2026)
Prime Medicine's (PRME) quarterly Current Deferred Revenue came in at $7.3 million in Q1 2026, down 10.88% YoY from $8.2 million in Q1 2025, and down 6.44% on a QoQ basis from $7.8 million in Q4 2025.
Prime Medicine (PRME) Current Deferred Revenue (2024 - 2026) Analysis & Trends
Prime Medicine (PRME) has 3 years of Current Deferred Revenue data on file, last reported at $7.3 million in Q1 2026.
- Quarterly Current Deferred Revenue fell 10.88% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (down 10.88% YoY) and the FY2025 annual result came in at $7.8 million, up 10.32% from the prior year.
- Current Deferred Revenue fell to $7.3 million in Q1 2026, from $7.8 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $9.3 million in Q3 2024 to a low of $7.0 million in Q3 2025.
- A 3-year average of $7.9 million and a median of $7.8 million in 2025 frame the typical range for Current Deferred Revenue.
- The widest YoY moves for Current Deferred Revenue: up 10.32% in 2025, down 25.1% in 2025.
- Tracing PRME's Current Deferred Revenue over 3 years: stood at $7.1 million in 2024, then gained by 10.32% to $7.8 million in 2025, then decreased by 6.44% to $7.3 million in 2026.
- The last three Current Deferred Revenue figures came in at $7.3 million (Q1 2026), $7.8 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.93 Mn |
| Mar 31, 2026 | 7.32 Mn |
| Dec 31, 2025 | 7.82 Mn |
| Sep 30, 2025 | 6.95 Mn |
| Jun 30, 2025 | 8.32 Mn |
| Mar 31, 2025 | 8.21 Mn |
| Dec 31, 2024 | 7.09 Mn |
| Sep 30, 2024 | 9.28 Mn |